You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Research & Development
Veralox Therapeutics Submits IND to US FDA for Phase I Trial of VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Login
Username:

Password:


Related Headlines

Galibra Neuroscience's SSADH deficiency gene therapy receives FDA Orphan Drug and Rare Pediatric Disease Designations

Obsidian Therapeutics advances Agni-01 study with first patient enrolled in registration-enabling cohort

CVS Health expands GLP-1 weight management access through integrated care offering

Adyen to provide LillyDirect with payment technology services

Sanofi's MenQuadfi receives EU approval for infants from six weeks

Acurx receives FDA guidance supporting ibezapolstat Phase 3 development strategy

Zai Lab's zoci receives FDA orphan designation for neuroendocrine carcinomas

Biocon launches Yesafili biosimilar in US ophthalmology market

Ractigen Therapeutics IND application for RAG-1C receives FDA clearance

Pfizer reports positive Phase 3 results for LITFULO in nonsegmental vitiligo

European Commission approves RINVOQ for severe alopecia areata

Incyte's Opzelura approved in European Union for moderate atopic dermatitis

RTW Biotech portfolio company Yarrow Bioscience completes merger

Lupin's Diazepam Injection, USP receives US approval

Auxilium Health changes name to Aeris Biosciences

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026